I would also like to clarify that these targets exclude any potential contribution from Enjaymo. Our agreement with Sanofi to acquire the global rights to Enjaymo reaffirms our continuous ...

Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update. Recordati Industria Chimica e Farmaceutica SPA reported strong ...

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Meanwhile, Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

La Corte also said Recordati would unveil its 2025 outlook in February, along with preliminary 2024 results, taking into account its recent acquisition from Sanofi (SASY.PA), opens new tab of the ...

New drug Enjaymo recorded sales of €28 million in the quarter compared with €26 million in the previous quarter. Sanofi has sold global rights to Enjaymo to Recordati. The transaction is ...

Sanofi has won FDA approval for its sutimlimab ... The complement C1s-targeting antibody – given the brand name Enjaymo – has been cleared decrease the need for blood transfusions in patients ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.